GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
Clinical trial NCT07090538 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07090538
- Sponsor
- Chinese PLA General Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2026-08-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.